Kodiak Sciences, Inc. (KOD)
99.18
+4.92
(+5.22%)
USD |
NASDAQ |
Oct 09, 13:59
Kodiak Sciences Enterprise Value : 5.949B for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 5.949B |
| October 07, 2026 | 5.749B |
| October 06, 2026 | 5.829B |
| October 05, 2026 | 5.921B |
| October 02, 2026 | 5.961B |
| October 01, 2026 | 6.213B |
| September 30, 2026 | 5.983B |
| September 29, 2026 | 5.752B |
| September 28, 2026 | 5.677B |
| September 25, 2026 | 2.059B |
| September 24, 2026 | 2.114B |
| September 23, 2026 | 2.007B |
| September 22, 2026 | 2.151B |
| September 21, 2026 | 2.064B |
| September 18, 2026 | 2.082B |
| September 17, 2026 | 2.091B |
| September 16, 2026 | 2.086B |
| September 15, 2026 | 2.100B |
| September 14, 2026 | 2.109B |
| September 11, 2026 | 2.093B |
| September 10, 2026 | 2.092B |
| September 09, 2026 | 2.149B |
| September 08, 2026 | 2.230B |
| September 04, 2026 | 2.249B |
| September 03, 2026 | 2.311B |
| Date | Value |
|---|---|
| September 02, 2026 | 2.383B |
| September 01, 2026 | 2.355B |
| August 31, 2026 | 2.374B |
| August 28, 2026 | 2.397B |
| August 27, 2026 | 2.485B |
| August 26, 2026 | 2.498B |
| August 25, 2026 | 2.506B |
| August 24, 2026 | 2.365B |
| August 21, 2026 | 2.435B |
| August 20, 2026 | 2.530B |
| August 19, 2026 | 2.544B |
| August 18, 2026 | 2.581B |
| August 17, 2026 | 2.602B |
| August 14, 2026 | 2.625B |
| August 13, 2026 | 2.539B |
| August 12, 2026 | 2.754B |
| August 11, 2026 | 2.673B |
| August 10, 2026 | 2.754B |
| August 07, 2026 | 2.877B |
| August 06, 2026 | 2.879B |
| August 05, 2026 | 2.767B |
| August 04, 2026 | 2.722B |
| August 03, 2026 | 2.529B |
| July 31, 2026 | 2.639B |
| July 30, 2026 | 2.697B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 71.17B |
| AbbVie, Inc. | 545.69B |
| Mirum Pharmaceuticals, Inc. | 5.592B |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.64M |
| Total Expenses (Quarterly) | 65.64M |
| EPS Diluted (Quarterly) | -1.048 |
| Earnings Yield | -4.23% |
| Normalized Earnings Yield | -4.228 |